Fig. 5: MHC-I‒E7‒cmEry demonstrates favorable safety profile in non-human primates.
From: Developing an erythrocyte‒MHC-I conjugate for cancer treatment
a Pharmacokinetic study of MHC-I‒E7‒cmEry in cynomolgus macaques. The monkeys were administered with Far-Red dye-labeled cmEry or MHC-I‒E7‒cmEry every 21 days. Blood was collected at specified time points (cmEry, n = 2; MHC-I‒E7‒cmEry, n = 4). b Safety assessments of MHC-I‒E7‒cmEry in cynomolgus macaques. Routine hematology (HGB, lymphocytes), coagulation tests (PT), serum biochemistry (TG, ALT), lymphocyte count and systolic arterial pressure were assessed throughout the experiment. c Representative images of H&E staining. A complete necropsy was performed on all animals. All organs were subjected to histopathological examination in each group using H&E staining. Scale bar: 20 μm. Data are presented as means ± SEM.
